

CITATION REPORT

List of articles citing

Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach

DOI: 10.1245/s10434-019-07785-y

Annals of Surgical Oncology, 2019, 26, 4326-4336.

Source: <https://exaly.com/paper-pdf/72746973/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
27	Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer. <i>Journal of the American College of Surgeons</i> , 2020 , 231, 434-447.e2	4.4	13
26	How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?. <i>Annals of Surgical Oncology</i> , 2020 , 27, 4702-4710	3.1	17
25	Axillary Response in Patients Undergoing Neoadjuvant Endocrine Treatment for Node-Positive Breast Cancer: Systematic Literature Review and NCDB Analysis. <i>Annals of Surgical Oncology</i> , 2020 , 27, 4669-4677	3.1	11
24	Gauging the efficacy of neoadjuvant endocrine therapy in breast cancer patients with known axillary disease. <i>Journal of Surgical Oncology</i> , 2020 , 122, 619	2.8	5
23	Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021 , 28, 1358-1367	3.1	10
22	Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art. <i>Cancers</i> , 2021 , 13,	6.6	1
21	Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic. <i>Breast Cancer Research and Treatment</i> , 2021 , 188, 249-258	4.4	7
20	The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment. <i>Cancers</i> , 2021 , 13,	6.6	4
19	Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy. <i>Annals of Surgical Oncology</i> , 2021 , 28, 8729-8739	3.1	1
18	Characterizing Occult Nodal Disease Within a Clinically Node-Negative, Neoadjuvant Breast Cancer Population. <i>Clinical Breast Cancer</i> , 2021 ,	3	1
17	Controversies in Breast Cancer Surgery. <i>Surgical Clinics of North America</i> , 2021 , 101, 1033-1044	4	1
16	Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 1928-1933	3.6	1
15	Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes. <i>Annals of Surgical Oncology</i> , 2021 , 28, 5730-5741	3.1	4
14	Neoadjuvant Endocrine Therapy in Clinical Practice: A Review. <i>JAMA Oncology</i> , 2021 , 7, 1700-1708	13.4	4
13	The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like Breast Cancers and Its Prognostic Significance: Results from a Single-Institution Prospective Cohort Study.. <i>Current Oncology</i> , 2022 , 29, 2199-2210	2.8	0
12	Surgical Considerations and Expectations in Patients Receiving Neoadjuvant Chemotherapy and Neoadjuvant Endocrine Therapy. 2022 , 219-238		
11	Adjuvant Versus Neoadjuvant Systemic Therapy. 2022 , 151-167		

10	Assessment of preoperative axillary nodal disease burden: breast MRI in locally advanced breast cancer before, during and after neoadjuvant endocrine therapy. <i>BMC Cancer</i> , 2022 , 22,	4.8	○
9	The prevalence and predictors of adjuvant chemotherapy use among patients treated with neoadjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> ,	4.4	○
8	Regional Nodal Management After Preoperative Systemic Therapy. <i>Seminars in Radiation Oncology</i> , 2022 , 32, 228-236	5.5	○
7	What Is the Role of Neoadjuvant Endocrine Therapy for Breast Cancer?. 2022 ,	1	○
6	Surgical Management of the Axilla for Breast Cancer. 2023 , 37, 51-77		○
5	Contemporary approaches to the axilla in breast cancer. 2022 ,		○
4	Local Regional Recurrence Rates Are Low Following Neoadjuvant Endocrine Therapy: What Are the Remaining Barriers to its Widespread Adoption?.		○
3	Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer.		○
2	Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact..		○
1	Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact.		○